QSI stock news · Quantum-Si Inc
Get alerts for QSI
Follow Quantum-Si Inc (QSI) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for QSIQuantum-Si Inc: Other Events (QSI)
Good for QSIQuantum-Si regained Nasdaq's $1 minimum closing-price rule, ending its current listing warning. It must keep meeting the rule to avoid another warning.
Quantum-Si Stock Booms: What's Going On?
Good for QSIQuantum-Si said its Proteus sequencer can identify 19 of 20 amino acids. This moves its planned product forward, though the kit and final amino acid remain unfinished.
Here are 12 health care stocks that changed a lot during Friday's trading.
NeutralQuantum-Si shares rose 30% in Friday trading, but the report gives no company news behind the move. It does not change the picture of the company's business.
On Thursday, 12 health care stocks saw big price changes, with Nexalin Technology jumping up 77.8%.
NeutralQuantum-Si shares rose 28.97% during Thursday's session, but the article gives no company news explaining the move, so its business outlook is unchanged.
12 health care stocks are changing a lot before the market opens on Thursday.
NeutralQuantum-Si shares rose 12.14%. The article reports a share move, not business news that changes the company's outlook.
What's making Quantum-Si's stock go up on Tuesday?
Good for QSIQuantum-Si reported interim tests where Proteus found more peptides and proteins than its Platinum Pro platform. The results support its product prospects, though one larger comparison is only projected.
On Tuesday, 12 health care stocks saw big price changes during the day.
NeutralQuantum-Si's shares rose 22.66% to $0.98, but the story gives no business reason. It reports no new company fact, so the outlook is unchanged.
Complete Record: Quantum-Si's Earnings Call for Q2 2026
NeutralQuantum-Si's Q2 2026 earnings call disclosed a delay in the launch of its Proteus product to Q2 2027, alongside a significant workforce reduction aimed at cost-saving. The decrease in revenue and the strategic shift towards application-oriented products may lead to negative investor sentiment and impact the stock's performance in the near term.